Reinventing the fight against bacteria, one phage at a time.

Antimicrobial resistance in orthopedics: microbial insights, clinical impact, and the necessity of a multidisciplinary approach—a review  Julia L VAN AGTMAAL 1, Mariëlle VERHEUL 2,3, Lieve VONKEN 4, Kato HELSEN 5, Marian G VARGAS GUERRERO 1, Sanne W G VAN HOOGSTRATEN 1, Bianca J HURCK 1, Giulia PILLA 6, Isabell TRINH 6, Gert-Jan DE BRUIJN 5, Henrik P CALUM 7, Mark G J DE BOER 2, Bart G PIJLS 3, and Jacobus J C ARTS 1,8 1 Department of Orthopaedic Surgery, Research Institute CAPHRI, Maastricht University Medical Center, Maastricht, the Netherlands; 2 Department of Infectious Diseases, Leiden University Medical Center, Leiden, the Netherlands; 3 Department of Orthopedics, Leiden University Medical Center, Leiden, the Netherlands; 4 Department of Health Promotion, Faculty of Health, Medicine & Life Sciences, Research Institute CAPHRI, Maastricht University, Maastricht, the Netherlands; 5 Department of Communication Studies, University of Antwerp, Antwerp, Belgium; 6 Nostics B. V.,...

University of Florida Grants Exclusive Worldwide License to Phageolytix for Breakthrough Phage Therapy Technology UF research advances global fight against antibiotic-resistant infections through strategic industry partnership The University of Florida has granted an exclusive worldwide license to Phageolytix, a biotechnology company specializing in innovative antimicrobial solutions, for multi-indication treatments with bacteriophage cocktails developed by UF researchers. This strategic partnership will accelerate the translation of cutting-edge university research into commercial therapeutic solutions addressing the critical global challenge of antibiotic-resistant bacterial infections. Translating UF Research into Life-Saving Treatments The licensed technology, developed by researchers in the University of Florida’s College of Medicine-Jacksonville, represents a breakthrough in phage-based cocktail therapy. Phage-based cocktail therapy is a medical treatment using a combination of b...

Phage Therapy May Treat Drug Resistance in Patients With Cystic Fibrosis, Study Finds June 13, 2025 "Yale's university researchers find a new approach to combatting antimicrobial resistance. Antimicrobial resistance, in which germs like bacteria and fungi no longer respond to medicines, is a rising global threat. When antibiotics and other drugs become ineffective, infections can become difficult or impossible to treat, leading to an increase in the spread and severity of disease. In a new study, published in Nature Medicine , a team of researchers at the Center for Phage Biology and Therapy at Yale discovered a novel approach that may revolutionize the fight against antimicrobial resistance. Jon Koff, MD, with a patient Credit: Robert A. Lisak For the study, the research team investigated the use of phage therapy—the use of viruses, or phages, to target and kill bacteria—to help patients with cystic fibrosis, a disease in which antimicrobial resistance is a significant issue....

Building the evidence for the use of bacteriophage therapy : This paper was published by the World Health Organization on the 26th of May 2025. We do not have any of the legal rights from the article and just want to share this tremendous and quite unusual paper from the WHO which underlines very well how phage therapy is really about and how to use it in the future. We took some of the most interesting parts to have a quite short but complete summary. Good reading ! Source :  www.tuftscimar.org Overview Bacteriophages (‎phages)‎ are a promising tool for addressing antimicrobial resistance, targeting harmful bacteria without disrupting beneficial microbiota. Safe for humans, they can enhance antibiotic treatments, particularly against resistant bacteria. The WHO Regional Office for Europe and the Global Antimicrobial Resistance Research and Development Hub are advancing evidence for phage applications through the “Vintage Innovation” initiative, adopting a One Health approach acros...